165 related articles for article (PubMed ID: 11527782)
1. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults.
Schackman BR; Goldie SJ; Weinstein MC; Losina E; Zhang H; Freedberg KA
Am J Public Health; 2001 Sep; 91(9):1456-63. PubMed ID: 11527782
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
3. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
4. When to start antiretroviral therapy in resource-limited settings.
Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
Schackman BR; Freedberg KA; Weinstein MC; Sax PE; Losina E; Zhang H; Goldie SJ
Arch Intern Med; 2002 Nov; 162(21):2478-86. PubMed ID: 12437408
[TBL] [Abstract][Full Text] [Related]
6. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards.
Johri M; David Paltiel A; Goldie SJ; Freedberg KA
Med Care; 2002 May; 40(5):429-41. PubMed ID: 11961477
[TBL] [Abstract][Full Text] [Related]
7. Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid.
Kahn JG; Haile B; Kates J; Chang S
Am J Public Health; 2001 Sep; 91(9):1464-73. PubMed ID: 11527783
[TBL] [Abstract][Full Text] [Related]
8. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
9. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
[TBL] [Abstract][Full Text] [Related]
10. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Simpson KN; Rajagopalan R; Dietz B
Adv Ther; 2009 Feb; 26(2):185-93. PubMed ID: 19219410
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
[TBL] [Abstract][Full Text] [Related]
13. [Budget impact analysis of antiretroviral therapy. A reflection based on the GESIDA guidelines].
Grupo de trabajo de la Cohorte VACH
Gac Sanit; 2012; 26(6):541-6. PubMed ID: 22498716
[TBL] [Abstract][Full Text] [Related]
14. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.
Sax PE; Sloan CE; Schackman BR; Grant PM; Rong J; Zolopa AR; Powderly W; Losina E; Freedberg KA;
HIV Clin Trials; 2010; 11(5):248-59. PubMed ID: 21126955
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
[TBL] [Abstract][Full Text] [Related]
16. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
[TBL] [Abstract][Full Text] [Related]
17. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.
Wolf LL; Ricketts P; Freedberg KA; Williams-Roberts H; Hirschhorn LR; Allen-Ferdinand K; Rodriguez WR; Divi N; Wong MT; Losina E
J Acquir Immune Defic Syndr; 2007 Dec; 46(4):463-71. PubMed ID: 18077836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
